HDAC1 and neoplasm: This study aims to investigate the therapeutic effects of peritumoral EA combined with HDAC1 inhibitor on tumor growth, specifically focusing on the the potential of peritumoral EA as a novel therapeutic strategy to enhance immune responses for TNBC in mice.